Rigorous Methodology and Ethical Considerations in a maternal Ebola Vaccine Trial
This study, registered prospectively with ClinicalTrials.gov (NCT04556526) on September 21, 2020, employed a meticulously designed methodology to evaluate the safety and immunogenicity of an Ebola vaccine in pregnant women and their infants. The research prioritizes both scientific rigor and ethical conduct,demonstrating a commitment to robust data and responsible research practices. This detailed overview outlines the key methodological approaches and ethical considerations implemented throughout the trial.
Participant Tracking and Data Integrity
The study adhered to the Consolidated Standards of Reporting Trials (CONSORT) guidelines for transparent reporting of participant flow. Detailed tracking was maintained from initial screening through enrollment, randomization, vaccination, and completion of follow-up. A comprehensive assessment of protocol deviations – categorized as major (potentially impacting endpoint evaluation) or minor – was conducted and reported by study group. Baseline demographic characteristics were thoroughly described for each group to ensure comparability.
Robust adverse Event Monitoring and Analysis
A primary focus was placed on the diligent monitoring and analysis of adverse events.The frequency and percentage of pre-defined primary adverse outcomes were tabulated by group and trimester of pregnancy.Maternal and fetal outcomes were carefully tracked from randomization through six weeks postpartum, with participants who discontinued the study without reporting outcomes excluded to maintain data integrity. Serious Adverse Events (SAEs) were tabulated for both mothers and infants,with each participant counted only once per event,nonetheless of recurrence.To ensure comprehensive data capture, efforts were made to obtain missing information regarding the severity and relationship of Adverse Events (AEs) to the study vaccine. While missing data were not imputed, a pragmatic approach was adopted: AEs with missing severity or relationship were still recorded as reported events but excluded from analyses requiring that specific information (e.g., grade 3 severity analysis). This approach maximizes the use of available data while acknowledging limitations.
Immunological Assessment: Precision and Standardization
The immunological response to the vaccine was assessed through the measurement of anti-EBOV GP-specific binding antibody concentrations. Geometric Mean Concentrations (GMCs) with 95% Confidence Intervals (CIs) were calculated at each time point. Sample positivity (proportion of quantifiable responses) and responder rates (≥2.5-fold increase from baseline) were also determined, utilizing Clopper-Pearson exact 95% CIs.
To address the limitations of assay quantification, values below the Lower Limit of Quantification (LLOQ) were imputed with half the LLOQ, and values above the Upper Limit of Quantification (ULOQ) were imputed with the ULOQ for GMC calculations.For fold change calculations, LLOQ and ULOQ were used as imputation values for below- and above-range results, respectively. This standardized approach minimizes bias and ensures accurate representation of the immunological response.
Correlation analysis: Exploring Maternal-Infant Antibody Transfer
A post-hoc correlation analysis was performed to investigate potential associations between antibody concentrations in mothers (predose, 21 days post-dose 2, postpartum day 1, and 365 days post-dose 1), cord blood (postpartum day 1), and infants (14 weeks of age).Partial Spearman correlation coefficients, controlling for maternal trimester at randomization, were calculated and visualized through correlation plots, providing insights into the potential transfer of maternal immunity to infants.
Self-reliant Data Monitoring and ethical Oversight
Patient safety was paramount. An independent Data and Safety Monitoring committee (IDMC), comprised of experts in obstetrics, pediatrics, and statistics, rigorously reviewed safety data twice at the study’s outset and then monthly throughout the trial.The study received approval from local ethics review committees and was conducted in full compliance with ethical guidelines.
Local Collaboration and Capacity Building
This research was conducted in close collaboration with local researchers at the Center for Family health Research (CFHR), ensuring local ownership and relevance. Local researchers were integral to all phases of the study, from design and implementation to data ownership, intellectual property, and authorship. The research directly addresses regional health priorities and was conducted in partnership with the Rwandan Ministry of Health. while formal local capacity building plans were not included, the collaborative approach fostered knowledge transfer and strengthened local research expertise. The study acknowledged the potential for participant risk and implemented robust safety procedures, as detailed in the manuscript.
This study exemplifies a commitment to rigorous scientific methodology, ethical research practices, and collaborative partnerships, ultimately contributing valuable knowledge to the field of maternal and infant vaccinology. Further details on the research design are available in the Nature Portfolio Reporting Summary [http://www.nature.com/articles/s41591-025-03932-z#MOESM2](http://www.nature.com/articles/s41591-025-0393